Wall Street Zen Upgrades Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) to “Sell”

Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) was upgraded by equities researchers at Wall Street Zen from a “strong sell” rating to a “sell” rating in a research note issued on Saturday.

Other equities analysts also recently issued research reports about the stock. Weiss Ratings upgraded shares of Senseonics Holdings, Inc. Common Stock from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, July 28th. HC Wainwright cut their price objective on shares of Senseonics Holdings, Inc. Common Stock from $18.50 to $14.00 and set a “buy” rating for the company in a report on Tuesday, May 12th. Mizuho cut their price objective on shares of Senseonics Holdings, Inc. Common Stock from $20.00 to $18.00 and set an “outperform” rating for the company in a report on Wednesday, July 15th. Finally, Stifel Nicolaus reduced their price objective on shares of Senseonics Holdings, Inc. Common Stock from $9.00 to $8.00 and set a “hold” rating for the company in a research note on Monday, May 11th. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $17.20.

Senseonics Holdings, Inc. Common Stock Stock Performance

Shares of SENS opened at $7.02 on Friday. The business has a 50-day moving average price of $5.85. Senseonics Holdings, Inc. Common Stock has a fifty-two week low of $4.79 and a fifty-two week high of $11.58. The stock has a market cap of $293.44 million, a price-to-earnings ratio of -3.15 and a beta of 1.01. The company has a current ratio of 6.74, a quick ratio of 6.40 and a debt-to-equity ratio of 0.62.

Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.08). The firm had revenue of $14.48 million during the quarter. Senseonics Holdings, Inc. Common Stock had a negative net margin of 225.09% and a negative return on equity of 165.80%. As a group, research analysts predict that Senseonics Holdings, Inc. Common Stock will post -2.38 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Douglas A. Roeder bought 22,686 shares of Senseonics Holdings, Inc. Common Stock stock in a transaction on Tuesday, May 12th. The stock was acquired at an average price of $5.56 per share, with a total value of $126,134.16. Following the acquisition, the director directly owned 144,635 shares of the company’s stock, valued at $804,170.60. This represents a 18.60% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 4.70% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Senseonics Holdings, Inc. Common Stock

A number of institutional investors and hedge funds have recently modified their holdings of the company. J.Safra Asset Management Corp bought a new position in shares of Senseonics Holdings, Inc. Common Stock in the second quarter valued at approximately $636,000. Kestra Advisory Services LLC bought a new stake in Senseonics Holdings, Inc. Common Stock during the 1st quarter worth approximately $68,000. GSK plc bought a new stake in Senseonics Holdings, Inc. Common Stock during the 4th quarter worth approximately $60,000. State of Wyoming purchased a new stake in Senseonics Holdings, Inc. Common Stock in the 2nd quarter worth approximately $67,000. Finally, Cetera Investment Advisers bought a new position in Senseonics Holdings, Inc. Common Stock in the 1st quarter valued at $85,000. 12.36% of the stock is owned by hedge funds and other institutional investors.

Senseonics Holdings, Inc. Common Stock Company Profile

Senseonics Holdings, Inc develops and commercializes long-term implantable continuous glucose monitoring (CGM) systems for people with diabetes. The company’s primary product family is the Eversense system, which combines a small subcutaneously implanted sensor, a removable external transmitter, and companion smartphone applications to provide continuous glucose readings and alerts. Senseonics positions its technology as an alternative to wearable patch-style CGMs by offering multi-month sensor longevity and on-body vibration alerts delivered through the transmitter.

Senseonics supports clinical and commercial activities that include research and development, regulatory engagement, manufacturing and distribution, and training for healthcare providers who perform sensor insertion and removal.